Pharmaceutical development company EctoPharma has been awarded £70,000 to fund research into Ryboquin, a product that has been shown to improve the efficacy of chemotherapy.
Ryboquin uses new nano-technology to deliver gene-blocking RNA direct-to-cancer cells in the body, halting or significantly reducing tumour growth.
Research carried out by the London School of Pharmacy has produced positive results in controlling pancreatic tumour growth. The £70,000 grant will be used to investigate the product’s effect on refractory prostate cancer.
CEO Alan Walker said that he hopes the work will boost the life sciences sector in Scotland, adding: “There is enormous global demand for a product which can boost the effectiveness of chemotherapeutic agents in the fight against a number of common cancers. Ryboquin has the potential to revolutionise cancer treatments across the globe.”
The grant is the maximum amount given by Scottish Enterprise’s SMART: SCOTLAND Scheme, which supports innovative research and development projects within small and medium sized enterprises in Scotland.
Dr Chris McNab, SMART: SCOTLAND Programme Executive at Scottish Enterprise, added: “This project has the potential to bring hope to cancer sufferers and their families worldwide, as well as growing Scotland’s reputation as a global centre of innovation in life sciences.”